A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Manuscript Number: 


Daniel L. Alkon, Jeffrey Benison, David Crockford, Martin R. Farlow, Elaine Grenier, Richard E. Thompson, Alan J. Tuchman, Lee-Jen Wei, Susanne Wilke


Daniel L. Alkon

  • Consulting Fees:
    Consulting fees are $60,000 from NeuroDiagnostics LLC and $300,000 from Neurotrope Bioscience.
    260,000 shares and 130,000 options, both from Neurotrope Bioscience.

Jeffrey Benison

  • Equity:
    I own shares of stock

David Crockford

  • Equity:
    Employee stock options yet to be exercised. No equity ownership.
    Neurotrope, Inc. as Vice President, Regulatory Affairs

Martin R. Farlow

  • Nothing to Disclose

Elaine Grenier

  • Equity:
    Employee stock options
    I am the Executive Director of Clinical Operations for Neurotrope.

Richard E. Thompson

  • Consulting Fees:
    I was paid by the sponsoring, Neurotrope Bioscience, for statistical consulting for this manuscript. Consulting fees for work on this manuscript totaled less than $20,000.

Alan J. Tuchman

  • Consulting Fees:
    consulting fees from Neurotrope Inc.
    Oncolytics Biotech, 10 shares Johnson & Johnson 1405 shares Teva Pharmaceuticals 1000 shares

Lee-Jen Wei

  • Consulting Fees:
    I have done statistical consultation for several drug companies and serve on the scientific advisory boards for three companies.
    For one of the scientific board, I do receive stock option.

Susanne Wilke

  • Equity:
    I own stock and warrants at ~1% of NTRP
    I am on a patent for Veryex Pharmaceuticals, unrelated to the field of Alzheimer’s